尽管季度业绩有所改善，瑞思迈仍出现下滑

2026-08-07 22:07

Although ResMed (RMD) reported fiscal 2026 Q4 results after Thursday's closing bell that beat on both lines, the stock is down ~6% in Friday morning trading as the respiratory medical device maker fell short on adjusted gross margin and operating income.
Q4 Non-GAAP EPS of $2.95 compares to $2.55 in the year-ago period.
ResMed was negatively impacted in the quarter by $42M worth of field safety notification expenses for Astral respirators, some of which had a leak issue.
The company also raised its quarterly dividend by 10% to $0.66.
"We maintain our Neutral rating for now as we hear investor concerns that sales growth is lower than prior and a potential US return from competitor Philips (PHG) remains unknown," Citi said in a note.

More on ResMed